Table 1 Risk modeling of clinical response using MPS class and CS/DS metabolism pathway enrichment scores

From: Metabolic pathway-based subtypes associate glycan biosynthesis and treatment response in head and neck cancer

a

Endpoint

Model with MPS

Model without MPS

Final variables

Risk score P-value, HR (95% CI)

C-index (95%, 85% CI)

Final variables

Risk score P-value, HR (95% CI)

C-index (95%, 85% CI)

OS

MPS, ECE, Resection margin status, LVI

0.001, 2.565 (1.443–4.560)

0.741 (0.603-0.878, 0.640-0.842)

ECE, Resection margin status, LVI

0.032, 1.698 (1.048–2.751)

0.761 (0.632–0.890, 0.666-0.855)

RFS

MPS, ECE, LVI

<0.001, 2.542 (1.530–4.222)

0.815 (0.714-0.916, 0.741-0.889)

ECE, LVI

0.024, 2.182 (1.630–2.489)

0.738 (0.598–0.879, 0.635-0.842)

LR-RFS

MPS, ECE, LVI

0.227, 1.382 (0.818–2.337)

0.597 (0.403-0.790, 0.454-0.739)

ECE, LVI

0.744, 1.086 (0.661–1.786)

0.585 (0.377–0.792, 0.432–0.737)

b

Endpoint

P-value

Adj. P-value

HR (95% CI)

OS

0.014

0.016

2.867 (1.240–6.625)

RFS

0.006

0.014

3.121 (1.395–6.981)

LR-RFS

0.009

0.014

3.023 (1.326–6.894)

DSS

0.005

0.014

7.136 (1.825–27.91)

FFR

0.009

0.014

4.646 (1.459–14.79)

LRC

0.159

0.159

3.180 (0.636–15.910)

OS (GSE65858)

0.004

–

3.427 (1.476–7.957)

OS (GSE41613)

0.005

–

2.782 (1.367–5.665)

  1. Multivariable Cox Proportional-Hazards (Cox PH) analysis results assessment with MPS and modeling without the inclusion of MPS on the LMU-KKG HPV-negative cohort (n = 145) (a) Prognostic association of CS/DS metabolism enrichment scores in univariable Cox PH analysis for the LMU-KKG HPV-negative (n = 145), and GSE65858 (n = 176) and GSE41613 (n = 96) cohorts as validation (b) OS overall survival, RFS recurrence-free survival, LR-RFS locoregional recurrence-free survival, DSS disease-specific survival, FFR freedom from recurrence, LRC locoregional control, HR hazard ratio, C-index concordance-index, CSPG chondroitin sulfate proteoglycan, IHC immunohistochemistry.
Back to article page